SIHUAN PHARM (00460.HK): bireociclib indication added to national NRDL

On 16 November 2026, SIHUAN PHARM (00460.HK) said a new indication of bireociclib, from its Xuanzhu unit, was added to China 2026 national reimbursement list.
Key Highlights:
  • The new indication is first-line treatment of HR+/HER2- advanced breast cancer combined with an aromatase inhibitor.
  • All three approved indications of bireociclib are now on the national reimbursement list.

NewTimeSpace News: On 16 November 2026, Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 00460) said a new indication for bireociclib tablets, developed by its non-wholly-owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd. (stock code: 02575), has been added to China's 2026 national reimbursement drug list. The new indication covers first-line treatment of HR+/HER2- advanced breast cancer in combination with an aromatase inhibitor, and the list takes effect on 1 January 2027.

All three indications approved in mainland China for bireociclib are now on the national reimbursement list, giving reimbursement coverage across first-, second- and later-line treatment of HR+/HER2- advanced breast cancer. Bireociclib, sold under the brand name Xuanyuening, is the first approved CDK2/4/6 inhibitor in China. The Board expects the inclusion to broaden the patient base and speed up hospital access and clinical adoption.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.